JP2021523938A5 - - Google Patents
Info
- Publication number
- JP2021523938A5 JP2021523938A5 JP2021510564A JP2021510564A JP2021523938A5 JP 2021523938 A5 JP2021523938 A5 JP 2021523938A5 JP 2021510564 A JP2021510564 A JP 2021510564A JP 2021510564 A JP2021510564 A JP 2021510564A JP 2021523938 A5 JP2021523938 A5 JP 2021523938A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- mixture
- pharmaceutically acceptable
- neurosteroid
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667100P | 2018-05-04 | 2018-05-04 | |
| US62/667,100 | 2018-05-04 | ||
| US16/403,100 | 2019-05-03 | ||
| US16/403,100 US20190337975A1 (en) | 2018-05-04 | 2019-05-03 | Neurosteroid derivatives and uses thereof |
| PCT/IB2019/000517 WO2019211668A2 (en) | 2018-05-04 | 2019-05-03 | Neurosteroid derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523938A JP2021523938A (ja) | 2021-09-09 |
| JP2021523938A5 true JP2021523938A5 (https=) | 2022-05-02 |
| JPWO2019211668A5 JPWO2019211668A5 (https=) | 2022-05-02 |
Family
ID=68384780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510564A Pending JP2021523938A (ja) | 2018-05-04 | 2019-05-03 | 神経ステロイド誘導体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190337975A1 (https=) |
| EP (1) | EP3788055A4 (https=) |
| JP (1) | JP2021523938A (https=) |
| CN (1) | CN112823164A (https=) |
| AR (1) | AR116659A1 (https=) |
| AU (1) | AU2019264032A1 (https=) |
| CA (1) | CA3099089A1 (https=) |
| PY (1) | PY1934080A (https=) |
| TW (1) | TW202014192A (https=) |
| UY (1) | UY38213A (https=) |
| WO (1) | WO2019211668A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| CN115348864A (zh) * | 2020-02-05 | 2022-11-15 | 纯技术Lyt股份有限公司 | 神经甾体的脂质前药 |
| MX2022010620A (es) * | 2020-02-27 | 2022-11-30 | Brii Biosciences Inc | Profarmacos de esteroides neuroactivos. |
| IL315509A (en) * | 2022-03-18 | 2024-11-01 | Marinus Pharmaceuticals Inc | Genaxolone medication matrims |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB748846A (en) * | 1953-10-28 | 1956-05-09 | Vitamins Ltd | A process for the manufacture of pregnan-3(-a)-ol-20-one and derivatives thereof |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| KR100338287B1 (ko) * | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| US20060009432A1 (en) * | 2004-07-09 | 2006-01-12 | Roger Whiting | Use of neurosteroids to treat neuropathic pain |
| WO2011120044A1 (en) * | 2010-03-26 | 2011-09-29 | Duke University | Conjugated neuroactive steroid compositions and methods of use |
| FR2973031B1 (fr) * | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US20170022245A1 (en) * | 2013-11-26 | 2017-01-26 | Biopharma Works | Ganaxolone derivatives for treatment of central nervous systems disorders |
| EP3641779B1 (en) * | 2017-06-23 | 2024-02-28 | The Board of Trustees of the University of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| CN109666055A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 调节中枢神经治疗抑郁症的化合物及其用途 |
-
2019
- 2019-05-03 US US16/403,100 patent/US20190337975A1/en not_active Abandoned
- 2019-05-03 WO PCT/IB2019/000517 patent/WO2019211668A2/en not_active Ceased
- 2019-05-03 CA CA3099089A patent/CA3099089A1/en active Pending
- 2019-05-03 TW TW108115447A patent/TW202014192A/zh unknown
- 2019-05-03 AU AU2019264032A patent/AU2019264032A1/en not_active Abandoned
- 2019-05-03 EP EP19796480.2A patent/EP3788055A4/en not_active Withdrawn
- 2019-05-03 AR ARP190101187A patent/AR116659A1/es not_active Application Discontinuation
- 2019-05-03 PY PY201901934080A patent/PY1934080A/es unknown
- 2019-05-03 UY UY38213A patent/UY38213A/es unknown
- 2019-05-03 JP JP2021510564A patent/JP2021523938A/ja active Pending
- 2019-05-03 CN CN201980033110.9A patent/CN112823164A/zh active Pending
-
2021
- 2021-08-02 US US17/392,004 patent/US20210363173A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523938A5 (https=) | ||
| JP6951506B2 (ja) | 皮膚の炎症を処置するためのｐｕｆａの使用 | |
| JPWO2019211668A5 (https=) | ||
| BE1013477A3 (fr) | Formulation. | |
| CA2869676C (en) | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat | |
| JP2021523938A (ja) | 神経ステロイド誘導体およびその使用 | |
| ES2261570T3 (es) | Medicamento basado en gestagenos para aplicacion por via dermica que contiene acido ascorbico asi como sales del mismo. | |
| ES2253423T3 (es) | Formulacion de un ester de testosterona para uso humano. | |
| RU2690659C2 (ru) | Композиции для местного применения, содержащие кортикостероид | |
| KR20200052934A (ko) | 경피 제제 | |
| JPS6341887B2 (https=) | ||
| JP2022517724A (ja) | テストステロンの活性エステル誘導体、組成物、およびそれらの使用 | |
| JPS60172925A (ja) | 胆石溶解剤 | |
| JP2005533036A (ja) | 油性溶液の自己投与型避妊注射 | |
| MC2150A1 (fr) | Utilisation de derives d'acides alkylphophoriques pour la lutte contre les maladies du type psoriasis | |
| ES2939366T3 (es) | Formulaciones que contienen extractos lipófilos de plantas comestibles especiadas útiles para controlar el dolor y la inflamación | |
| US3541209A (en) | Method of alleviating hypertrophic conditions | |
| UA80703C2 (en) | Pharmaceutical composition comprising etonogestrel esters and use thereof for contraception and hormone replacement therapy | |
| ITMI20121205A1 (it) | Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione | |
| JP7134329B2 (ja) | ウンデカン酸テストステロンを含む安定した薬学的組成物 | |
| JP6786252B2 (ja) | 皮膚用の医薬組成物 | |
| CA3187883A1 (en) | Topical composition | |
| HK40021662A (en) | Use of pufas for treating skin inflammation | |
| JPH083073A (ja) | 経皮吸収促進剤及び皮膚外用剤 | |
| SA01210722B1 (ar) | تكوين صيدلي يحتوي على فولفسترانت fulvestrant |